MF Researcher Database

Researcher Database

Advance

Horiike Atsushi

■FacultyMedical Oncology
■PositionExtraordinary Professor
Last Updated :2025/11/18

Researcher

基本情報

Profile and Settings

  • 氏名

    Horiike Atsushi

Affiliation

  • Medical Oncology, Extraordinary Professor

Location

  • University Hospital

Degree

  • Doctor of Medical Science, Toho University, Mar. 2019

Achievements

Published Papers

  • Relationship between the combination of platelet count and neutrophil-lymphocyte ratio and prognosis of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study., Kashimura Saeko;Sato Miki;Inagaki Takahito;Kin Masaoki;Manabe Ryo;Kusumoto Sojiro;Horiike Atsushi;Tsunoda Takuya;Kogo Mari, Thoracic cancer, 15(28), Aug. 2024, Peer-reviewed
  • Relationship between the combination of platelet count and neutrophil-lymphocyte ratio and prognosis of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study., Kashimura Saeko;Sato Miki;Inagaki Takahito;Kin Masaoki;Manabe Ryo;Kusumoto Sojiro;Horiike Atsushi;Tsunoda Takuya;Kogo Mari, Thoracic cancer, 15(28), Aug. 2024, Peer-reviewed
  • Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody., Murayama Masakazu;Hosonuma Masahiro;Kuramasu Atsuo;Kobayashi Sei;Sasaki Akiko;Baba Yuta;Narikawa Yoichiro;Toyoda Hitoshi;Isobe Junya;Funayama Eiji;Tajima Kohei;Sasaki Aya;Maruyama Yuki;Yamazaki Yoshitaka;Shida Midori;Hamada Kazuyuki;Hirasawa Yuya;Tsurui Toshiaki;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Suzuki Risako;Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Sambe Takehiko;Tsuji Mayumi;Wada Satoshi;Kobayashi Shinichi;Shimane Toshikazu;Tsunoda Takuya;Kobayashi Hitome;Kiuchi Yuji;Yoshimura Kiyoshi, Scientific reports, 14(1), May 2024, Peer-reviewed
  • Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors., Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, Onishi N, Shimizu T, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Mura E, Takenoshita S, Numajiri K, Okabe N, Yoshimura K, Tsuji M, Kiuchi Y, Yajima T, Ishida H, Suzuki H, Yamochi T, Kobayashi S, Tsunoda T, Wada S., Front Immunol, 14:1260492, Sep. 2023, Peer-reviewed, DOI:10.3389/fimmu.2023.1260492
  • Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor., Kazuyuki Hamada, Junya Isobe, Kouya Hattori, Masahiro Hosonuma, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, Midori Shida, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Yuji Kiuchi, Shinichi Kobayashi, Atsuo Kuramasu, Atsushi Horiike, Yun-Gi Kim, Takuya Tsunoda and Kiyoshi Yoshimura, Front Immunol., 14:1164724, May 2023, Peer-reviewed, DOI:10.3389/fimmu.2023.1164724
  • The PD-L1/22C3 assay for primary lung cancer is feasible for daily clinical practice irrespective of the diagnostic procedure, SUGANUMA Hiromitsu;KUSUMOTO Sojiro;MANABE Ryo;KISHINO Yasunari;ENDO Tetsuya;ANDO Koichi;ISHIDA Hiroo;HORIIKE Atsushi;TANAKA Akihiko;TAKEI Hidefumi;YAMOCHI Toshiko;TSUNODA Takuya;SAGARA Hironori, Showa Univ J Med Sci, 34(2):64 - 77, Jun. 2022, Peer-reviewed, DOI:https://doi.org/10.15369/sujms.34.64
  • First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset., Miyako Satouchi; Kaname Nosaki; Toshiaki Takahashi; Kazuhiko Nakagawa; Keisuke Aoe; Takayasu Kurata; Akimasa Sekine; Atsushi Horiike; Tatsuro Fukuhara; Shunichi Sugawara; Shigeki Umemura; Hideo Saka; Isamu Okamoto; Nobuyuki Yamamoto; Hiroshi Sakai; Kazuma Kishi; Nobuyuki Katakami; Hidehito Horinouchi; Toyoaki Hida; Hiroaki Okamoto; Shinji Atagi; Tatsuo Ohira; Shi Rong Han; Kazuo Noguchi; Victoria Ebiana; Katsuyuki Hotta, Cancer science, 112(12):5000 - 5010, Dec. 2021
  • First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset., Miyako Satouchi; Kaname Nosaki; Toshiaki Takahashi; Kazuhiko Nakagawa; Keisuke Aoe; Takayasu Kurata; Akimasa Sekine; Atsushi Horiike; Tatsuro Fukuhara; Shunichi Sugawara; Shigeki Umemura; Hideo Saka; Isamu Okamoto; Nobuyuki Yamamoto; Hiroshi Sakai; Kazuma Kishi; Nobuyuki Katakami; Hidehito Horinouchi; Toyoaki Hida; Hiroaki Okamoto; Shinji Atagi; Tatsuo Ohira; Shi Rong Han; Kazuo Noguchi; Victoria Ebiana; Katsuyuki Hotta, Cancer science, 112(12):5000 - 5010, Dec. 2021
  • EGFR-TKI既治療症例に対するダコミチニブ療法の検討(TOPGAN2020-02), 椎原 淳; 田中 寿志; 坂本 博昭; 川嶋 庸介; 丹保 裕一; 谷本 梓; 堀池 篤; 宮内 栄作; 土屋 裕子; 西尾 誠人; 大柳 文義, 肺癌, 61(6):601 - 601, Oct. 2021
  • EGFR-TKI既治療症例に対するダコミチニブ療法の検討(TOPGAN2020-02), 椎原 淳; 田中 寿志; 坂本 博昭; 川嶋 庸介; 丹保 裕一; 谷本 梓; 堀池 篤; 宮内 栄作; 土屋 裕子; 西尾 誠人; 大柳 文義, 肺癌, 61(6):601 - 601, Oct. 2021
  • 肺がんに対する薬物療法の最前線, 堀池　篤, 昭和学士会雑誌, 81(3):131 - 138, Aug. 2021, Peer-reviewed
  • Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer., Tsukasa Hasegawa; Noriko Yanagitani; Fumiyoshi Ohyanagi; Keita Kudo; Atsushi Horiike; Yuichi Tambo; Shingo Nishikawa; Ryo Ariyasu; Ken Uchibori; Satoru Kitazono; Makoto Nishio, International journal of clinical oncology, 26(3):507 - 514, Mar. 2021
  • Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer., Tsukasa Hasegawa; Noriko Yanagitani; Fumiyoshi Ohyanagi; Keita Kudo; Atsushi Horiike; Yuichi Tambo; Shingo Nishikawa; Ryo Ariyasu; Ken Uchibori; Satoru Kitazono; Makoto Nishio, International journal of clinical oncology, 26(3):507 - 514, Mar. 2021
  • Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer., Tsukasa Hasegawa; Noriko Yanagitani; Fumiyoshi Ohyanagi; Keita Kudo; Atsushi Horiike; Yuichi Tambo; Shingo Nishikawa; Ryo Ariyasu; Ken Uchibori; Satoru Kitazono; Makoto Nishio, International journal of clinical oncology, 26(3):507 - 514, Mar. 2021
  • A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors., Kiyohiro Ando; Kazuyuki Hamada; Midori Shida; Ryotaro Ohkuma; Yutaro Kubota; Atsushi Horiike; Hiroto Matsui; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Makoto Watanabe; Rie Onoue; Junji Tsurutani; Kiyoshi Yoshimura; Takuya Tsunoda; Shinichi Kobayashi; Satoshi Wada, Cancer immunology, immunotherapy : CII, 70(2):337 - 348, Feb. 2021
  • A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors., Kiyohiro Ando; Kazuyuki Hamada; Midori Shida; Ryotaro Ohkuma; Yutaro Kubota; Atsushi Horiike; Hiroto Matsui; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Makoto Watanabe; Rie Onoue; Junji Tsurutani; Kiyoshi Yoshimura; Takuya Tsunoda; Shinichi Kobayashi; Satoshi Wada, Cancer immunology, immunotherapy : CII, 70(2):337 - 348, Feb. 2021
  • A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors., Kiyohiro Ando; Kazuyuki Hamada; Midori Shida; Ryotaro Ohkuma; Yutaro Kubota; Atsushi Horiike; Hiroto Matsui; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Makoto Watanabe; Rie Onoue; Junji Tsurutani; Kiyoshi Yoshimura; Takuya Tsunoda; Shinichi Kobayashi; Satoshi Wada, Cancer immunology, immunotherapy : CII, 70(2):337 - 348, Feb. 2021
  • High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer, Ryotaro Ohkuma; Erica Yada; Shumpei Ishikawa; Daisuke Komura; Yutaro Kubota; Kazuyuki Hamada; Atsushi Horiike; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Midori Shida; Makoto Watanabe; Rie Onoue; Kiyohiro Ando; Junji Tsurutani; Kiyoshi Yoshimura; Tetsuro Sasada; Takeshi Aoki; Masahiko Murakami; Tomoko Norose; Nobuyuki Ohike; Masafumi Takimoto; Shinichi Kobayashi; Takuya Tsunoda; Satoshi Wada, INTERNATIONAL JOURNAL OF ONCOLOGY, 58(1):57 - 69, Jan. 2021
  • High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer, Ryotaro Ohkuma; Erica Yada; Shumpei Ishikawa; Daisuke Komura; Yutaro Kubota; Kazuyuki Hamada; Atsushi Horiike; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Midori Shida; Makoto Watanabe; Rie Onoue; Kiyohiro Ando; Junji Tsurutani; Kiyoshi Yoshimura; Tetsuro Sasada; Takeshi Aoki; Masahiko Murakami; Tomoko Norose; Nobuyuki Ohike; Masafumi Takimoto; Shinichi Kobayashi; Takuya Tsunoda; Satoshi Wada, INTERNATIONAL JOURNAL OF ONCOLOGY, 58(1):57 - 69, Jan. 2021
  • High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer, Ryotaro Ohkuma; Erica Yada; Shumpei Ishikawa; Daisuke Komura; Yutaro Kubota; Kazuyuki Hamada; Atsushi Horiike; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Midori Shida; Makoto Watanabe; Rie Onoue; Kiyohiro Ando; Junji Tsurutani; Kiyoshi Yoshimura; Tetsuro Sasada; Takeshi Aoki; Masahiko Murakami; Tomoko Norose; Nobuyuki Ohike; Masafumi Takimoto; Shinichi Kobayashi; Takuya Tsunoda; Satoshi Wada, INTERNATIONAL JOURNAL OF ONCOLOGY, 58(1):57 - 69, Jan. 2021
  • ニボルマブによる重症免疫関連有害事象治療中のサイトメガロウイルス感染に注意を要した1例, 網野 喜彬; 植松 慎矢; 吉澤 孝浩; 内堀 健; 堀池 篤; 西尾 誠人, 日本呼吸器学会誌, 10(1):33 - 36, Jan. 2021
  • ニボルマブによる重症免疫関連有害事象治療中のサイトメガロウイルス感染に注意を要した1例, 網野 喜彬; 植松 慎矢; 吉澤 孝浩; 内堀 健; 堀池 篤; 西尾 誠人, 日本呼吸器学会誌, 10(1):33 - 36, Jan. 2021
  • ニボルマブによる重症免疫関連有害事象治療中のサイトメガロウイルス感染に注意を要した1例, 網野 喜彬; 植松 慎矢; 吉澤 孝浩; 内堀 健; 堀池 篤; 西尾 誠人, 日本呼吸器学会誌, 10(1):33 - 36, Jan. 2021
  • The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer., Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Watanabe Makoto;Onoue Rie;Ando Kiyohiro;Tsurutani Junji;Yoshimura Kiyoshi;Aoki Takeshi;Murakami Masahiko;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, Pancreas, 50(2), 2021, Peer-reviewed
  • Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer., Kubota Yutaro;Yoshimura Kiyoshi;Hamada Kazuyuki;Hirasawa Yuya;Shida Midori;Taniguchi Makoto;Matsui Hiroto;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Suzuki Norihiro;Ohkuma Ryotaro;Sambe Takehiko;Ishida Hiroo;Horiike Atsushi;Wada Satoshi;Tsurutani Junji;Iwamoto Sanju;Uchida Naoki;Kiuchi Yuji;Kobayashi Shinichi;Tsunoda Takuya, In vivo (Athens, Greece), 35(3), 2021, Peer-reviewed
  • A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy., Hirasawa Yuya;Yoshimura Kiyoshi;Matsui Hiroto;Kubota Yutaro;Ishida Hiroo;Arai Jun;Sakaki Masashi;Oguro Nao;Shida Midori;Taniguchi Makoto;Hamada Kazuyuki;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Ohkuma Ryotaro;Sambe Takehiko;Horiike Atsushi;Imamura Chiyo K;Shiozawa Eisuke;Wada Satoshi;Tsurutani Junji;Iwamoto Sanju;Uchida Naoki;Kiuchi Yuji;Tate Genshu;Kobayashi Shinichi;Tsunoda Takuya, Medicine, 100(23), 2021, Peer-reviewed
  • First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset., Miyako Satouchi; Kaname Nosaki; Toshiaki Takahashi; Kazuhiko Nakagawa; Keisuke Aoe; Takayasu Kurata; Akimasa Sekine; Atsushi Horiike; Tatsuro Fukuhara; Shunichi Sugawara; Shigeki Umemura; Hideo Saka; Isamu Okamoto; Nobuyuki Yamamoto; Hiroshi Sakai; Kazuma Kishi; Nobuyuki Katakami; Hidehito Horinouchi; Toyoaki Hida; Hiroaki Okamoto; Shinji Atagi; Tatsuo Ohira; Shi Rong Han; Kazuo Noguchi; Victoria Ebiana; Katsuyuki Hotta, Cancer science, 111(12):4480 - 4489, Dec. 2020
  • First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset., Miyako Satouchi; Kaname Nosaki; Toshiaki Takahashi; Kazuhiko Nakagawa; Keisuke Aoe; Takayasu Kurata; Akimasa Sekine; Atsushi Horiike; Tatsuro Fukuhara; Shunichi Sugawara; Shigeki Umemura; Hideo Saka; Isamu Okamoto; Nobuyuki Yamamoto; Hiroshi Sakai; Kazuma Kishi; Nobuyuki Katakami; Hidehito Horinouchi; Toyoaki Hida; Hiroaki Okamoto; Shinji Atagi; Tatsuo Ohira; Shi Rong Han; Kazuo Noguchi; Victoria Ebiana; Katsuyuki Hotta, Cancer science, 111(12):4480 - 4489, Dec. 2020
  • First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset., Miyako Satouchi; Kaname Nosaki; Toshiaki Takahashi; Kazuhiko Nakagawa; Keisuke Aoe; Takayasu Kurata; Akimasa Sekine; Atsushi Horiike; Tatsuro Fukuhara; Shunichi Sugawara; Shigeki Umemura; Hideo Saka; Isamu Okamoto; Nobuyuki Yamamoto; Hiroshi Sakai; Kazuma Kishi; Nobuyuki Katakami; Hidehito Horinouchi; Toyoaki Hida; Hiroaki Okamoto; Shinji Atagi; Tatsuo Ohira; Shi Rong Han; Kazuo Noguchi; Victoria Ebiana; Katsuyuki Hotta, Cancer science, 111(12):4480 - 4489, Dec. 2020
  • High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer., Ohkuma Ryotaro;Yada Erica;Ishikawa Shumpei;Komura Daisuke;Kubota Yutaro;Hamada Kazuyuki;Horiike Atsushi;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Shida Midori;Watanabe Makoto;Onoue Rie;Ando Kiyohiro;Tsurutani Junji;Yoshimura Kiyoshi;Sasada Tetsuro;Aoki Takeshi;Murakami Masahiko;Norose Tomoko;Ohike Nobuyuki;Takimoto Masafumi;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, International journal of oncology, 58(1), Nov. 2020, Peer-reviewed
  • 実臨床でのDurvalumab投与可否のDecision Making Factorに関する検討, 上浪 健; 田中 寿志; 宮内 栄作; 川嶋 庸介; 大柳 文義; 齊木 雅史; 酒谷 俊雄; 堀池 篤; 有安 亮; 谷本 梓; 丹保 裕一; 園田 智明; 神山 潤二; 工藤 慶太; 土屋 裕子; 西尾 誠人, 肺癌, 60(6):661 - 661, Oct. 2020
  • 実臨床でのDurvalumab投与可否のDecision Making Factorに関する検討, 上浪 健; 田中 寿志; 宮内 栄作; 川嶋 庸介; 大柳 文義; 齊木 雅史; 酒谷 俊雄; 堀池 篤; 有安 亮; 谷本 梓; 丹保 裕一; 園田 智明; 神山 潤二; 工藤 慶太; 土屋 裕子; 西尾 誠人, 肺癌, 60(6):661 - 661, Oct. 2020
  • 実臨床でのDurvalumab投与可否のDecision Making Factorに関する検討, 上浪 健; 田中 寿志; 宮内 栄作; 川嶋 庸介; 大柳 文義; 齊木 雅史; 酒谷 俊雄; 堀池 篤; 有安 亮; 谷本 梓; 丹保 裕一; 園田 智明; 神山 潤二; 工藤 慶太; 土屋 裕子; 西尾 誠人, 肺癌, 60(6):661 - 661, Oct. 2020
  • A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors., Ando Kiyohiro;Hamada Kazuyuki;Shida Midori;Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Matsui Hiroto;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Watanabe Makoto;Onoue Rie;Tsurutani Junji;Yoshimura Kiyoshi;Tsunoda Takuya;Kobayashi Shinichi;Wada Satoshi, Cancer immunology, immunotherapy : CII, 70(2), Aug. 2020, Peer-reviewed
  • Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors., Takehiro Tozuka; Satoru Kitazono; Hiroaki Sakamoto; Hiroshi Yoshida; Yoshiaki Amino; Shinya Uematsu; Takahiro Yoshizawa; Tsukasa Hasegawa; Ken Uchibori; Noriko Yanagitani; Atsushi Horiike; Takeshi Horai; Masahiro Seike; Akihiko Gemma; Makoto Nishio, BMC cancer, 20(1):207 - 207, Mar. 2020
  • Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors., Takehiro Tozuka; Satoru Kitazono; Hiroaki Sakamoto; Hiroshi Yoshida; Yoshiaki Amino; Shinya Uematsu; Takahiro Yoshizawa; Tsukasa Hasegawa; Ken Uchibori; Noriko Yanagitani; Atsushi Horiike; Takeshi Horai; Masahiro Seike; Akihiko Gemma; Makoto Nishio, BMC cancer, 20(1):207 - 207, Mar. 2020
  • Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors., Takehiro Tozuka; Satoru Kitazono; Hiroaki Sakamoto; Hiroshi Yoshida; Yoshiaki Amino; Shinya Uematsu; Takahiro Yoshizawa; Tsukasa Hasegawa; Ken Uchibori; Noriko Yanagitani; Atsushi Horiike; Takeshi Horai; Masahiro Seike; Akihiko Gemma; Makoto Nishio, BMC cancer, 20(1):207 - 207, Mar. 2020
  • Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial., Isamu Okamoto; Hiroshi Nokihara; Shogo Nomura; Seiji Niho; Shunichi Sugawara; Hidehito Horinouchi; Koichi Azuma; Yasuto Yoneshima; Haruyasu Murakami; Yukio Hosomi; Shinji Atagi; Tomohiro Ozaki; Atsushi Horiike; Yuka Fujita; Hiroaki Okamoto; Masahiko Ando; Nobuyuki Yamamoto; Yuichiro Ohe; Kazuhiko Nakagawa, JAMA oncology, 6(5):e196828, Mar. 2020
  • Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial., Isamu Okamoto; Hiroshi Nokihara; Shogo Nomura; Seiji Niho; Shunichi Sugawara; Hidehito Horinouchi; Koichi Azuma; Yasuto Yoneshima; Haruyasu Murakami; Yukio Hosomi; Shinji Atagi; Tomohiro Ozaki; Atsushi Horiike; Yuka Fujita; Hiroaki Okamoto; Masahiko Ando; Nobuyuki Yamamoto; Yuichiro Ohe; Kazuhiko Nakagawa, JAMA oncology, 6(5):e196828, Mar. 2020
  • Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial., Isamu Okamoto; Hiroshi Nokihara; Shogo Nomura; Seiji Niho; Shunichi Sugawara; Hidehito Horinouchi; Koichi Azuma; Yasuto Yoneshima; Haruyasu Murakami; Yukio Hosomi; Shinji Atagi; Tomohiro Ozaki; Atsushi Horiike; Yuka Fujita; Hiroaki Okamoto; Masahiko Ando; Nobuyuki Yamamoto; Yuichiro Ohe; Kazuhiko Nakagawa, JAMA oncology, 6(5):e196828, Mar. 2020
  • Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L)., Takashi Seto; Koichi Azuma; Takeharu Yamanaka; Shunichi Sugawara; Hiroshige Yoshioka; Kazushige Wakuda; Shinji Atagi; Yasuo Iwamoto; Hidetoshi Hayashi; Isamu Okamoto; Hideo Saka; Shigeki Mitsuoka; Daichi Fujimoto; Kazumi Nishino; Atsushi Horiike; Haruko Daga; Takashi Sone; Nobuyuki Yamamoto; Kazuhiko Nakagawa; Yoichi Nakanishi, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(8):793 - 803, Mar. 2020
  • Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L)., Takashi Seto; Koichi Azuma; Takeharu Yamanaka; Shunichi Sugawara; Hiroshige Yoshioka; Kazushige Wakuda; Shinji Atagi; Yasuo Iwamoto; Hidetoshi Hayashi; Isamu Okamoto; Hideo Saka; Shigeki Mitsuoka; Daichi Fujimoto; Kazumi Nishino; Atsushi Horiike; Haruko Daga; Takashi Sone; Nobuyuki Yamamoto; Kazuhiko Nakagawa; Yoichi Nakanishi, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(8):793 - 803, Mar. 2020
  • Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L)., Takashi Seto; Koichi Azuma; Takeharu Yamanaka; Shunichi Sugawara; Hiroshige Yoshioka; Kazushige Wakuda; Shinji Atagi; Yasuo Iwamoto; Hidetoshi Hayashi; Isamu Okamoto; Hideo Saka; Shigeki Mitsuoka; Daichi Fujimoto; Kazumi Nishino; Atsushi Horiike; Haruko Daga; Takashi Sone; Nobuyuki Yamamoto; Kazuhiko Nakagawa; Yoichi Nakanishi, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(8):793 - 803, Mar. 2020
  • Insulinoma-associated Protein 1 (INSM1) is a better marker for the diagnosis and prognosis estimation of small cell lung carcinoma than neuroendocrine phenotype markers such as chromogranin A, synaptophysin, and CD56., Sakakibara R; Kobayashi M; Takahashi N; Inamura K; Ninomiya H; Wakejima R; Kitazono S; Yanagitani N; Horiike A; Ichinose J; Matsuura Y; Nakao M; Mun M; Nishio M; Okumura S; Motoi N; Ito T; Miyazaki Y; Inase N; Ishikawa Y, American Journal of Surgical Pathology, 44(6):757 - 764, Feb. 2020
  • Insulinoma-associated Protein 1 (INSM1) is a better marker for the diagnosis and prognosis estimation of small cell lung carcinoma than neuroendocrine phenotype markers such as chromogranin A, synaptophysin, and CD56., Sakakibara R; Kobayashi M; Takahashi N; Inamura K; Ninomiya H; Wakejima R; Kitazono S; Yanagitani N; Horiike A; Ichinose J; Matsuura Y; Nakao M; Mun M; Nishio M; Okumura S; Motoi N; Ito T; Miyazaki Y; Inase N; Ishikawa Y, American Journal of Surgical Pathology, 44(6):757 - 764, Feb. 2020
  • Insulinoma-associated Protein 1 (INSM1) is a better marker for the diagnosis and prognosis estimation of small cell lung carcinoma than neuroendocrine phenotype markers such as chromogranin A, synaptophysin, and CD56., Sakakibara R; Kobayashi M; Takahashi N; Inamura K; Ninomiya H; Wakejima R; Kitazono S; Yanagitani N; Horiike A; Ichinose J; Matsuura Y; Nakao M; Mun M; Nishio M; Okumura S; Motoi N; Ito T; Miyazaki Y; Inase N; Ishikawa Y, American Journal of Surgical Pathology, 44(6):757 - 764, Feb. 2020
  • Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms., Noriko Yanagitani; Ken Uchibori; Sumie Koike; Mika Tsukahara; Satoru Kitazono; Takahiro Yoshizawa; Atsushi Horiike; Fumiyoshi Ohyanagi; Yuichi Tambo; Shingo Nishikawa; Naoya Fujita; Ryohei Katayama; Makoto Nishio, Cancer science, 111(3):932 - 939, Jan. 2020
  • Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms., Noriko Yanagitani; Ken Uchibori; Sumie Koike; Mika Tsukahara; Satoru Kitazono; Takahiro Yoshizawa; Atsushi Horiike; Fumiyoshi Ohyanagi; Yuichi Tambo; Shingo Nishikawa; Naoya Fujita; Ryohei Katayama; Makoto Nishio, Cancer science, 111(3):932 - 939, Jan. 2020
  • Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms., Noriko Yanagitani; Ken Uchibori; Sumie Koike; Mika Tsukahara; Satoru Kitazono; Takahiro Yoshizawa; Atsushi Horiike; Fumiyoshi Ohyanagi; Yuichi Tambo; Shingo Nishikawa; Naoya Fujita; Ryohei Katayama; Makoto Nishio, Cancer science, 111(3):932 - 939, Jan. 2020
  • Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer., Tsukasa Hasegawa; Noriko Yanagitani; Hirofumi Utsumi; Hiroshi Wakui; Hiroaki Sakamoto; Takehiro Tozuka; Hiroshi Yoshida; Yoshiaki Amino; Shinya Uematsu; Takahiro Yoshizawa; Ken Uchibori; Satoru Kitazono; Atsushi Horiike; Takeshi Horai; Kazuyoshi Kuwano; Makoto Nishio, Anticancer research, 39(12):6851 - 6857, Dec. 2019
  • Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer., Tsukasa Hasegawa; Noriko Yanagitani; Hirofumi Utsumi; Hiroshi Wakui; Hiroaki Sakamoto; Takehiro Tozuka; Hiroshi Yoshida; Yoshiaki Amino; Shinya Uematsu; Takahiro Yoshizawa; Ken Uchibori; Satoru Kitazono; Atsushi Horiike; Takeshi Horai; Kazuyoshi Kuwano; Makoto Nishio, Anticancer research, 39(12):6851 - 6857, Dec. 2019
  • Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer., Tsukasa Hasegawa; Noriko Yanagitani; Hirofumi Utsumi; Hiroshi Wakui; Hiroaki Sakamoto; Takehiro Tozuka; Hiroshi Yoshida; Yoshiaki Amino; Shinya Uematsu; Takahiro Yoshizawa; Ken Uchibori; Satoru Kitazono; Atsushi Horiike; Takeshi Horai; Kazuyoshi Kuwano; Makoto Nishio, Anticancer research, 39(12):6851 - 6857, Dec. 2019
  • 局所進行非小細胞肺癌に対するCBDCA/nab-PTXを用いた同時化学放射線療法の第I/II相試験, 浦田 佳子; 土屋 裕子; 佐々木 智成; 山口 博之; 平野 勝也; 堀池 篤; 細川 忍; 森永 亮太郎; 小宮 一利; 井上 孝治; 藤田 結花; 豊澤 亮; 木村 智樹; 高橋 孝輔; 西川 和男; 岸本 淳司; 中西 洋一; 岡本 勇, 肺癌, 59(6):672 - 672, Nov. 2019
  • 局所進行非小細胞肺癌に対するCBDCA/nab-PTXを用いた同時化学放射線療法の第I/II相試験, 浦田 佳子; 土屋 裕子; 佐々木 智成; 山口 博之; 平野 勝也; 堀池 篤; 細川 忍; 森永 亮太郎; 小宮 一利; 井上 孝治; 藤田 結花; 豊澤 亮; 木村 智樹; 高橋 孝輔; 西川 和男; 岸本 淳司; 中西 洋一; 岡本 勇, 肺癌, 59(6):672 - 672, Nov. 2019
  • 局所進行非小細胞肺癌に対するCBDCA/nab-PTXを用いた同時化学放射線療法の第I/II相試験, 浦田 佳子; 土屋 裕子; 佐々木 智成; 山口 博之; 平野 勝也; 堀池 篤; 細川 忍; 森永 亮太郎; 小宮 一利; 井上 孝治; 藤田 結花; 豊澤 亮; 木村 智樹; 高橋 孝輔; 西川 和男; 岸本 淳司; 中西 洋一; 岡本 勇, 肺癌, 59(6):672 - 672, Nov. 2019
  • 希少肺癌に対する免疫チェックポイント阻害薬の治療効果についての検討, 吉田 寛; 内堀 健; 坂本 博昭; 戸塚 猛大; 網野 喜彬; 植松 慎矢; 長谷川 司; 吉澤 孝浩; 北園 聡; 柳谷 典子; 堀池 篤; 宝来 威; 西尾 誠人, 肺癌, 59(6):892 - 892, Nov. 2019
  • 希少肺癌に対する免疫チェックポイント阻害薬の治療効果についての検討, 吉田 寛; 内堀 健; 坂本 博昭; 戸塚 猛大; 網野 喜彬; 植松 慎矢; 長谷川 司; 吉澤 孝浩; 北園 聡; 柳谷 典子; 堀池 篤; 宝来 威; 西尾 誠人, 肺癌, 59(6):892 - 892, Nov. 2019
  • 希少肺癌に対する免疫チェックポイント阻害薬の治療効果についての検討, 吉田 寛; 内堀 健; 坂本 博昭; 戸塚 猛大; 網野 喜彬; 植松 慎矢; 長谷川 司; 吉澤 孝浩; 北園 聡; 柳谷 典子; 堀池 篤; 宝来 威; 西尾 誠人, 肺癌, 59(6):892 - 892, Nov. 2019
  • PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers, A. Drilon; G. Oxnard; L. Wirth; B. Besse; O. Gautschi; S.W.D. Tan; H. Loong; T. Bauer; Y.J. Kim; A. Horiike; K. Park; M. Shah; C. McCoach; L. Bazhenova; T. Seto; M. Brose; N. Pennell; J. Weiss; I. Matos; N. Peled; B.C. Cho; Y. Ohe; K. Reckamp; V. Boni; M. Satouchi; G. Falchook; W. Akerley; H. Daga; T. Sakamoto; J. Patel; N. Lakhani; F. Barlesi; M. Burkard; V. Zhu; V. Moreno Garcia; J. Medioni; M. Matrana; C. Rolfo; D.H. Lee; H. Nechushtan; M. Johnson; V. Velcheti; M. Nishio; R. Toyozawa; K. Ohashi; L. Song; J. Han; A. Spira; F. De Braud; K. Staal Rohrberg; S. Takeuchi; J. Sakakibara; S. Waqar; H. Kenmotsu; F. Wilson; B.Nair; E. Olek; J. Kherani; K. Ebata; E. Zhu; M. Nguyen; L. Yang; X. Huang; S. Cruickshank; S. Rothenberg; B. Solomon; K. Goto; V. Subbiah, Journal of Thoracic Oncology, 14(10):S6 - S7, Oct. 2019
  • PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers, A. Drilon; G. Oxnard; L. Wirth; B. Besse; O. Gautschi; S.W.D. Tan; H. Loong; T. Bauer; Y.J. Kim; A. Horiike; K. Park; M. Shah; C. McCoach; L. Bazhenova; T. Seto; M. Brose; N. Pennell; J. Weiss; I. Matos; N. Peled; B.C. Cho; Y. Ohe; K. Reckamp; V. Boni; M. Satouchi; G. Falchook; W. Akerley; H. Daga; T. Sakamoto; J. Patel; N. Lakhani; F. Barlesi; M. Burkard; V. Zhu; V. Moreno Garcia; J. Medioni; M. Matrana; C. Rolfo; D.H. Lee; H. Nechushtan; M. Johnson; V. Velcheti; M. Nishio; R. Toyozawa; K. Ohashi; L. Song; J. Han; A. Spira; F. De Braud; K. Staal Rohrberg; S. Takeuchi; J. Sakakibara; S. Waqar; H. Kenmotsu; F. Wilson; B.Nair; E. Olek; J. Kherani; K. Ebata; E. Zhu; M. Nguyen; L. Yang; X. Huang; S. Cruickshank; S. Rothenberg; B. Solomon; K. Goto; V. Subbiah, Journal of Thoracic Oncology, 14(10):S6 - S7, Oct. 2019
  • PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers, A. Drilon; G. Oxnard; L. Wirth; B. Besse; O. Gautschi; S.W.D. Tan; H. Loong; T. Bauer; Y.J. Kim; A. Horiike; K. Park; M. Shah; C. McCoach; L. Bazhenova; T. Seto; M. Brose; N. Pennell; J. Weiss; I. Matos; N. Peled; B.C. Cho; Y. Ohe; K. Reckamp; V. Boni; M. Satouchi; G. Falchook; W. Akerley; H. Daga; T. Sakamoto; J. Patel; N. Lakhani; F. Barlesi; M. Burkard; V. Zhu; V. Moreno Garcia; J. Medioni; M. Matrana; C. Rolfo; D.H. Lee; H. Nechushtan; M. Johnson; V. Velcheti; M. Nishio; R. Toyozawa; K. Ohashi; L. Song; J. Han; A. Spira; F. De Braud; K. Staal Rohrberg; S. Takeuchi; J. Sakakibara; S. Waqar; H. Kenmotsu; F. Wilson; B.Nair; E. Olek; J. Kherani; K. Ebata; E. Zhu; M. Nguyen; L. Yang; X. Huang; S. Cruickshank; S. Rothenberg; B. Solomon; K. Goto; V. Subbiah, Journal of Thoracic Oncology, 14(10):S6 - S7, Oct. 2019
  • Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer., Tsuchiya-Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I, The oncologist, 25(6):475-e891, Oct. 2019
  • Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer., Tsuchiya-Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I, The oncologist, 25(6):475-e891, Oct. 2019
  • Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer., Tsuchiya-Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I, The oncologist, 25(6):475-e891, Oct. 2019
  • Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients., Kitazono S; Sakai K; Yanagitani N; Ariyasu R; Yoshizawa T; Dotsu Y; Koyama J; Saiki M; Sonoda T; Nishikawa S; Uchibori K; Horiike A; Nishio K; Nishio M, Cancer science, 110(10):3350 - 3357, Oct. 2019
  • Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients., Kitazono S; Sakai K; Yanagitani N; Ariyasu R; Yoshizawa T; Dotsu Y; Koyama J; Saiki M; Sonoda T; Nishikawa S; Uchibori K; Horiike A; Nishio K; Nishio M, Cancer science, 110(10):3350 - 3357, Oct. 2019
  • Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients., Kitazono S; Sakai K; Yanagitani N; Ariyasu R; Yoshizawa T; Dotsu Y; Koyama J; Saiki M; Sonoda T; Nishikawa S; Uchibori K; Horiike A; Nishio K; Nishio M, Cancer science, 110(10):3350 - 3357, Oct. 2019
  • Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC., Amino Y; Kitazono S; Uematsu S; Hasegawa T; Yoshizawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Kasahara K; Nishio M, International journal of clinical oncology, 25(1):67 - 73, Sep. 2019
  • Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC., Amino Y; Kitazono S; Uematsu S; Hasegawa T; Yoshizawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Kasahara K; Nishio M, International journal of clinical oncology, 25(1):67 - 73, Sep. 2019
  • Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC., Amino Y; Kitazono S; Uematsu S; Hasegawa T; Yoshizawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Kasahara K; Nishio M, International journal of clinical oncology, 25(1):67 - 73, Sep. 2019
  • Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA., Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I, The oncologist, 24(8):1022 - 1026, Aug. 2019
  • Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA., Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I, The oncologist, 24(8):1022 - 1026, Aug. 2019
  • Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA., Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I, The oncologist, 24(8):1022 - 1026, Aug. 2019
  • Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody., Saiki M; Yoshizawa T; Dotsu Y; Ariyasu R; Koyama J; Sonoda T; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Horiike A; Nishio M, Lung cancer (Amsterdam, Netherlands), 133:4 - 9, Jul. 2019
  • Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody., Saiki M; Yoshizawa T; Dotsu Y; Ariyasu R; Koyama J; Sonoda T; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Horiike A; Nishio M, Lung cancer (Amsterdam, Netherlands), 133:4 - 9, Jul. 2019
  • Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody., Saiki M; Yoshizawa T; Dotsu Y; Ariyasu R; Koyama J; Sonoda T; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Horiike A; Nishio M, Lung cancer (Amsterdam, Netherlands), 133:4 - 9, Jul. 2019
  • Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer., Koyama J; Horiike A; Yoshizawa T; Dotsu Y; Ariyasu R; Saiki M; Sonoda T; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Ninomiya H; Ishikawa Y; Nishio M, Journal of thoracic disease, 11(5):1919 - 1928, May 2019
  • Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer., Koyama J; Horiike A; Yoshizawa T; Dotsu Y; Ariyasu R; Saiki M; Sonoda T; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Ninomiya H; Ishikawa Y; Nishio M, Journal of thoracic disease, 11(5):1919 - 1928, May 2019
  • Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer., Koyama J; Horiike A; Yoshizawa T; Dotsu Y; Ariyasu R; Saiki M; Sonoda T; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Ninomiya H; Ishikawa Y; Nishio M, Journal of thoracic disease, 11(5):1919 - 1928, May 2019
  • Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017., Takano N; Ariyasu R; Koyama J; Sonoda T; Saiki M; Kawashima Y; Oguri T; Hisakane K; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Ohyanagi F; Horiike A; Gemma A; Nishio M, Lung cancer (Amsterdam, Netherlands), 131:69 - 77, May 2019
  • Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017., Takano N; Ariyasu R; Koyama J; Sonoda T; Saiki M; Kawashima Y; Oguri T; Hisakane K; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Ohyanagi F; Horiike A; Gemma A; Nishio M, Lung cancer (Amsterdam, Netherlands), 131:69 - 77, May 2019
  • Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017., Takano N; Ariyasu R; Koyama J; Sonoda T; Saiki M; Kawashima Y; Oguri T; Hisakane K; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Ohyanagi F; Horiike A; Gemma A; Nishio M, Lung cancer (Amsterdam, Netherlands), 131:69 - 77, May 2019
  • Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer., Nokihara H; Nishio M; Yamamoto N; Fujiwara Y; Horinouchi H; Kanda S; Horiike A; Ohyanagi F; Yanagitani N; Nguyen L; Yaron Y; Borgman A; Tamura T, Clinical lung cancer, 20(3):e317 - e328, May 2019
  • Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer., Nokihara H; Nishio M; Yamamoto N; Fujiwara Y; Horinouchi H; Kanda S; Horiike A; Ohyanagi F; Yanagitani N; Nguyen L; Yaron Y; Borgman A; Tamura T, Clinical lung cancer, 20(3):e317 - e328, May 2019
  • Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer., Nokihara H; Nishio M; Yamamoto N; Fujiwara Y; Horinouchi H; Kanda S; Horiike A; Ohyanagi F; Yanagitani N; Nguyen L; Yaron Y; Borgman A; Tamura T, Clinical lung cancer, 20(3):e317 - e328, May 2019
  • Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status., Koji Fukuda; Shinji Takeuchi; Sachiko Arai; Ryohei Katayama; Shigeki Nanjo; Azusa Tanimoto; Akihiro Nishiyama; Takayuki Nakagawa; Hirokazu Taniguchi; Takeshi Suzuki; Tadaaki Yamada; Hiroshi Nishihara; Hironori Ninomiya; Yuichi Ishikawa; Satoko Baba; Kengo Takeuchi; Atsushi Horiike; Noriko Yanagitani; Makoto Nishio; Seiji Yano, Cancer research, 79(7):1658 - 1670, Apr. 2019
  • Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status., Koji Fukuda; Shinji Takeuchi; Sachiko Arai; Ryohei Katayama; Shigeki Nanjo; Azusa Tanimoto; Akihiro Nishiyama; Takayuki Nakagawa; Hirokazu Taniguchi; Takeshi Suzuki; Tadaaki Yamada; Hiroshi Nishihara; Hironori Ninomiya; Yuichi Ishikawa; Satoko Baba; Kengo Takeuchi; Atsushi Horiike; Noriko Yanagitani; Makoto Nishio; Seiji Yano, Cancer research, 79(7):1658 - 1670, Apr. 2019
  • Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status., Koji Fukuda; Shinji Takeuchi; Sachiko Arai; Ryohei Katayama; Shigeki Nanjo; Azusa Tanimoto; Akihiro Nishiyama; Takayuki Nakagawa; Hirokazu Taniguchi; Takeshi Suzuki; Tadaaki Yamada; Hiroshi Nishihara; Hironori Ninomiya; Yuichi Ishikawa; Satoko Baba; Kengo Takeuchi; Atsushi Horiike; Noriko Yanagitani; Makoto Nishio; Seiji Yano, Cancer research, 79(7):1658 - 1670, Apr. 2019
  • First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors., Shimomura A; Yamamoto N; Kondo S; Fujiwara Y; Suzuki S; Yanagitani N; Horiike A; Kitazono S; Ohyanagi F; Doi T; Kuboki Y; Kawazoe A; Shitara K; Ohno I; Banerji U; Sundar R; Ohkubo S; Calleja EM; Nishio M, Molecular cancer therapeutics, 18(3):531 - 540, Mar. 2019
  • First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors., Shimomura A; Yamamoto N; Kondo S; Fujiwara Y; Suzuki S; Yanagitani N; Horiike A; Kitazono S; Ohyanagi F; Doi T; Kuboki Y; Kawazoe A; Shitara K; Ohno I; Banerji U; Sundar R; Ohkubo S; Calleja EM; Nishio M, Molecular cancer therapeutics, 18(3):531 - 540, Mar. 2019
  • First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors., Shimomura A; Yamamoto N; Kondo S; Fujiwara Y; Suzuki S; Yanagitani N; Horiike A; Kitazono S; Ohyanagi F; Doi T; Kuboki Y; Kawazoe A; Shitara K; Ohno I; Banerji U; Sundar R; Ohkubo S; Calleja EM; Nishio M, Molecular cancer therapeutics, 18(3):531 - 540, Mar. 2019
  • Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance., Koutaroh Okada; Mitsugu Araki; Takuya Sakashita; Biao Ma; Ryo Kanada; Noriko Yanagitani; Atsushi Horiike; Sumie Koike; Tomoko Oh-Hara; Kana Watanabe; Keiichi Tamai; Makoto Maemondo; Makoto Nishio; Takeshi Ishikawa; Yasushi Okuno; Naoya Fujita; Ryohei Katayama, EBioMedicine, 41:105 - 119, Mar. 2019
  • Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance., Koutaroh Okada; Mitsugu Araki; Takuya Sakashita; Biao Ma; Ryo Kanada; Noriko Yanagitani; Atsushi Horiike; Sumie Koike; Tomoko Oh-Hara; Kana Watanabe; Keiichi Tamai; Makoto Maemondo; Makoto Nishio; Takeshi Ishikawa; Yasushi Okuno; Naoya Fujita; Ryohei Katayama, EBioMedicine, 41:105 - 119, Mar. 2019
  • Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance., Koutaroh Okada; Mitsugu Araki; Takuya Sakashita; Biao Ma; Ryo Kanada; Noriko Yanagitani; Atsushi Horiike; Sumie Koike; Tomoko Oh-Hara; Kana Watanabe; Keiichi Tamai; Makoto Maemondo; Makoto Nishio; Takeshi Ishikawa; Yasushi Okuno; Naoya Fujita; Ryohei Katayama, EBioMedicine, 41:105 - 119, Mar. 2019
  • Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing., Hidenori Mizugaki; Akinobu Hamada; Tatsuhiro Shibata; Fumie Hosoda; Hiromi Nakamura; Yusuke Okuma; Takehito Shukuya; Shigeki Umemura; Atsushi Horiike; Tomoya Fukui; Yoshihito Kogure; Haruko Daga; Yoshiko Urata; Kazuhiko Yamada; Sho Saeki; Yasuhito Fujisaka; Yukiko Nakamura; Mitsuo Sato; Tatsuya Yoshida; Takamasa Hotta; Satoshi Oizumi; Yasuhiro Fujiwara; Yuichiro Ohe; Yutaka Fujiwara, Lung cancer (Amsterdam, Netherlands), 128:20 - 25, Feb. 2019
  • Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing., Hidenori Mizugaki; Akinobu Hamada; Tatsuhiro Shibata; Fumie Hosoda; Hiromi Nakamura; Yusuke Okuma; Takehito Shukuya; Shigeki Umemura; Atsushi Horiike; Tomoya Fukui; Yoshihito Kogure; Haruko Daga; Yoshiko Urata; Kazuhiko Yamada; Sho Saeki; Yasuhito Fujisaka; Yukiko Nakamura; Mitsuo Sato; Tatsuya Yoshida; Takamasa Hotta; Satoshi Oizumi; Yasuhiro Fujiwara; Yuichiro Ohe; Yutaka Fujiwara, Lung cancer (Amsterdam, Netherlands), 128:20 - 25, Feb. 2019
  • Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing., Hidenori Mizugaki; Akinobu Hamada; Tatsuhiro Shibata; Fumie Hosoda; Hiromi Nakamura; Yusuke Okuma; Takehito Shukuya; Shigeki Umemura; Atsushi Horiike; Tomoya Fukui; Yoshihito Kogure; Haruko Daga; Yoshiko Urata; Kazuhiko Yamada; Sho Saeki; Yasuhito Fujisaka; Yukiko Nakamura; Mitsuo Sato; Tatsuya Yoshida; Takamasa Hotta; Satoshi Oizumi; Yasuhiro Fujiwara; Yuichiro Ohe; Yutaka Fujiwara, Lung cancer (Amsterdam, Netherlands), 128:20 - 25, Feb. 2019
  • Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab., Kawashima Y; Nishikawa S; Ninomiya H; Yoshida R; Takano N; Oguri T; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ishikawa Y; Nishio M, Internal medicine (Tokyo, Japan), 58(10):1479 - 1484, 2019
  • Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab., Kawashima Y; Nishikawa S; Ninomiya H; Yoshida R; Takano N; Oguri T; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ishikawa Y; Nishio M, Internal medicine (Tokyo, Japan), 58(10):1479 - 1484, 2019
  • Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab., Kawashima Y; Nishikawa S; Ninomiya H; Yoshida R; Takano N; Oguri T; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ishikawa Y; Nishio M, Internal medicine (Tokyo, Japan), 58(10):1479 - 1484, 2019
  • Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer., Yuko Kawano; Tomonari Sasaki; Hiroyuki Yamaguchi; Katsuya Hirano; Atsushi Horiike; Miyako Satouchi; Shinobu Hosokawa; Ryotaro Morinaga; Kazutoshi Komiya; Koji Inoue; Yuka Fujita; Ryo Toyozawa; Tomoki Kimura; Kosuke Takahashi; Kazuo Nishikawa; Junji Kishimoto; Yoichi Nakanishi; Isamu Okamoto, Lung cancer (Amsterdam, Netherlands), 125:136 - 141, Nov. 2018
  • Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer., Yuko Kawano; Tomonari Sasaki; Hiroyuki Yamaguchi; Katsuya Hirano; Atsushi Horiike; Miyako Satouchi; Shinobu Hosokawa; Ryotaro Morinaga; Kazutoshi Komiya; Koji Inoue; Yuka Fujita; Ryo Toyozawa; Tomoki Kimura; Kosuke Takahashi; Kazuo Nishikawa; Junji Kishimoto; Yoichi Nakanishi; Isamu Okamoto, Lung cancer (Amsterdam, Netherlands), 125:136 - 141, Nov. 2018
  • Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer., Yuko Kawano; Tomonari Sasaki; Hiroyuki Yamaguchi; Katsuya Hirano; Atsushi Horiike; Miyako Satouchi; Shinobu Hosokawa; Ryotaro Morinaga; Kazutoshi Komiya; Koji Inoue; Yuka Fujita; Ryo Toyozawa; Tomoki Kimura; Kosuke Takahashi; Kazuo Nishikawa; Junji Kishimoto; Yoichi Nakanishi; Isamu Okamoto, Lung cancer (Amsterdam, Netherlands), 125:136 - 141, Nov. 2018
  • Atezolizumab in Japanese Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study, Toyoaki Hida; Reiko Kaji; Miyako Satouchi; Norihiko Ikeda; Atsushi Horiike; Hiroshi Nokihara; Takashi Seto; Tomohisa Kawakami; Shintaro Nakagawa; Toshio Kubo, Clinical Lung Cancer, 19(4):e405 - e415, Jul. 2018
  • Atezolizumab in Japanese Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study, Toyoaki Hida; Reiko Kaji; Miyako Satouchi; Norihiko Ikeda; Atsushi Horiike; Hiroshi Nokihara; Takashi Seto; Tomohisa Kawakami; Shintaro Nakagawa; Toshio Kubo, Clinical Lung Cancer, 19(4):e405 - e415, Jul. 2018
  • Atezolizumab in Japanese Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study, Toyoaki Hida; Reiko Kaji; Miyako Satouchi; Norihiko Ikeda; Atsushi Horiike; Hiroshi Nokihara; Takashi Seto; Tomohisa Kawakami; Shintaro Nakagawa; Toshio Kubo, Clinical Lung Cancer, 19(4):e405 - e415, Jul. 2018
  • Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors, Makoto Nishio; Miyako Satouchi; Atsushi Horiike; Yoshitsugu Horio; Yoshinori Sunaga; Evelyne Ecstein-Fraisse; Toyoaki Hida, Japanese Journal of Clinical Oncology, 48(4):322 - 328, Apr. 2018
  • Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors, Makoto Nishio; Miyako Satouchi; Atsushi Horiike; Yoshitsugu Horio; Yoshinori Sunaga; Evelyne Ecstein-Fraisse; Toyoaki Hida, Japanese Journal of Clinical Oncology, 48(4):322 - 328, Apr. 2018
  • Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors, Makoto Nishio; Miyako Satouchi; Atsushi Horiike; Yoshitsugu Horio; Yoshinori Sunaga; Evelyne Ecstein-Fraisse; Toyoaki Hida, Japanese Journal of Clinical Oncology, 48(4):322 - 328, Apr. 2018
  • High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer, Ryo Ariyasu; Shingo Nishikawa; Ken Uchibori; Tomoko Oh-hara; Takahiro Yoshizawa; Yosuke Dotsu; Junji Koyama; Masafumi Saiki; Tomoaki Sonoda; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Naohiko Inase; Kazuo Kasahara; Makoto Nishio; Ryohei Katayama, Lung Cancer, 117:1 - 6, Mar. 2018
  • High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer, Ryo Ariyasu; Shingo Nishikawa; Ken Uchibori; Tomoko Oh-hara; Takahiro Yoshizawa; Yosuke Dotsu; Junji Koyama; Masafumi Saiki; Tomoaki Sonoda; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Naohiko Inase; Kazuo Kasahara; Makoto Nishio; Ryohei Katayama, Lung Cancer, 117:1 - 6, Mar. 2018
  • High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer, Ryo Ariyasu; Shingo Nishikawa; Ken Uchibori; Tomoko Oh-hara; Takahiro Yoshizawa; Yosuke Dotsu; Junji Koyama; Masafumi Saiki; Tomoaki Sonoda; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Naohiko Inase; Kazuo Kasahara; Makoto Nishio; Ryohei Katayama, Lung Cancer, 117:1 - 6, Mar. 2018
  • EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer, Tomoaki Sonoda; Shingo Nishikawa; Rie Sakakibara; Masafumi Saiki; Ryo Ariyasu; Junji Koyama; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Fumiyoshi Ohyanagi; Hironori Ninomiya; Yuichi Ishikawa; Makoto Nishio, Respiratory Medicine Case Reports, 24:19 - 21, Jan. 2018
  • EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer, Tomoaki Sonoda; Shingo Nishikawa; Rie Sakakibara; Masafumi Saiki; Ryo Ariyasu; Junji Koyama; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Fumiyoshi Ohyanagi; Hironori Ninomiya; Yuichi Ishikawa; Makoto Nishio, Respiratory Medicine Case Reports, 24:19 - 21, Jan. 2018
  • EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer, Tomoaki Sonoda; Shingo Nishikawa; Rie Sakakibara; Masafumi Saiki; Ryo Ariyasu; Junji Koyama; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Fumiyoshi Ohyanagi; Hironori Ninomiya; Yuichi Ishikawa; Makoto Nishio, Respiratory Medicine Case Reports, 24:19 - 21, Jan. 2018
  • Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer, Masafumi Saiki; Satoru Kitazono; Takahiro Yoshizawa; Yosuke Dotsu; Ryo Ariyasu; Junji Koyama; Tomoaki Sonoda; Ken Uchibori; Shingo Nishikawa; Noriko Yanagitani; Atsushi Horiike; Fumiyoshi Ohyanagi; Katsunori Oikado; Hironori Ninomiya; Kengo Takeuchi; Yuichi Ishikawa; Makoto Nishio, Clinical Lung Cancer, 19(5):435 - 440.e1, 2018
  • Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer, Masafumi Saiki; Satoru Kitazono; Takahiro Yoshizawa; Yosuke Dotsu; Ryo Ariyasu; Junji Koyama; Tomoaki Sonoda; Ken Uchibori; Shingo Nishikawa; Noriko Yanagitani; Atsushi Horiike; Fumiyoshi Ohyanagi; Katsunori Oikado; Hironori Ninomiya; Kengo Takeuchi; Yuichi Ishikawa; Makoto Nishio, Clinical Lung Cancer, 19(5):435 - 440.e1, 2018
  • Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer, Masafumi Saiki; Satoru Kitazono; Takahiro Yoshizawa; Yosuke Dotsu; Ryo Ariyasu; Junji Koyama; Tomoaki Sonoda; Ken Uchibori; Shingo Nishikawa; Noriko Yanagitani; Atsushi Horiike; Fumiyoshi Ohyanagi; Katsunori Oikado; Hironori Ninomiya; Kengo Takeuchi; Yuichi Ishikawa; Makoto Nishio, Clinical Lung Cancer, 19(5):435 - 440.e1, 2018
  • Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene, Masafumi Saiki; Fumiyoshi Ohyanagi; Ryo Ariyasu; Junji Koyama; Tomoaki Sonoda; Shingo Nishikawa; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Hironori Ninomiya; Yuichi Ishikawa; Makoto Nishio, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 47(12):1189 - 1192, Dec. 2017
  • Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene, Masafumi Saiki; Fumiyoshi Ohyanagi; Ryo Ariyasu; Junji Koyama; Tomoaki Sonoda; Shingo Nishikawa; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Hironori Ninomiya; Yuichi Ishikawa; Makoto Nishio, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 47(12):1189 - 1192, Dec. 2017
  • Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene, Masafumi Saiki; Fumiyoshi Ohyanagi; Ryo Ariyasu; Junji Koyama; Tomoaki Sonoda; Shingo Nishikawa; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Hironori Ninomiya; Yuichi Ishikawa; Makoto Nishio, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 47(12):1189 - 1192, Dec. 2017
  • EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer, Rie Sakakibara; Kentaro Inamura; Yuichi Tambo; Hironori Ninomiya; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Fumiyoshi Ohyanagi; Yosuke Matsuura; Masayuki Nakao; Mingyon Mun; Sakae Okumura; Naohiko Inase; Makoto Nishio; Noriko Motoi; Yuichi Ishikawa, CLINICAL LUNG CANCER, 18(5):527 - +, Sep. 2017
  • EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer, Rie Sakakibara; Kentaro Inamura; Yuichi Tambo; Hironori Ninomiya; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Fumiyoshi Ohyanagi; Yosuke Matsuura; Masayuki Nakao; Mingyon Mun; Sakae Okumura; Naohiko Inase; Makoto Nishio; Noriko Motoi; Yuichi Ishikawa, CLINICAL LUNG CANCER, 18(5):527 - +, Sep. 2017
  • EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer, Rie Sakakibara; Kentaro Inamura; Yuichi Tambo; Hironori Ninomiya; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Fumiyoshi Ohyanagi; Yosuke Matsuura; Masayuki Nakao; Mingyon Mun; Sakae Okumura; Naohiko Inase; Makoto Nishio; Noriko Motoi; Yuichi Ishikawa, CLINICAL LUNG CANCER, 18(5):527 - +, Sep. 2017
  • Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy, Ryo Ariyasu; Atsushi Horiike; Takahiro Yoshizawa; Yosuke Dotsu; Junji Koyama; Masafumi Saiki; Tomoaki Sonoda; Shingo Nishikawa; Satoru Kitazono; Noriko Yanagitani; Makoto Nishio, ANTICANCER RESEARCH, 37(8):4229 - 4232, Aug. 2017
  • Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy, Ryo Ariyasu; Atsushi Horiike; Takahiro Yoshizawa; Yosuke Dotsu; Junji Koyama; Masafumi Saiki; Tomoaki Sonoda; Shingo Nishikawa; Satoru Kitazono; Noriko Yanagitani; Makoto Nishio, ANTICANCER RESEARCH, 37(8):4229 - 4232, Aug. 2017
  • Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy, Ryo Ariyasu; Atsushi Horiike; Takahiro Yoshizawa; Yosuke Dotsu; Junji Koyama; Masafumi Saiki; Tomoaki Sonoda; Shingo Nishikawa; Satoru Kitazono; Noriko Yanagitani; Makoto Nishio, ANTICANCER RESEARCH, 37(8):4229 - 4232, Aug. 2017
  • Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib, Ryo Ariyasu; Atsushi Horiike; Junji Koyama; Masafumi Saiki; Tomoaki Sonoda; Yosuke Kawashima; Natsuki Takano; Tomoyo Oguri; Shingo Nishikawa; Satoru Kitazono; Noriko Yanagitani; Fumiyoshi Ohyanagi; Makoto Nishio, ANTI-CANCER DRUGS, 28(5):565 - 567, Jun. 2017
  • Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib, Ryo Ariyasu; Atsushi Horiike; Junji Koyama; Masafumi Saiki; Tomoaki Sonoda; Yosuke Kawashima; Natsuki Takano; Tomoyo Oguri; Shingo Nishikawa; Satoru Kitazono; Noriko Yanagitani; Fumiyoshi Ohyanagi; Makoto Nishio, ANTI-CANCER DRUGS, 28(5):565 - 567, Jun. 2017
  • Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib, Ryo Ariyasu; Atsushi Horiike; Junji Koyama; Masafumi Saiki; Tomoaki Sonoda; Yosuke Kawashima; Natsuki Takano; Tomoyo Oguri; Shingo Nishikawa; Satoru Kitazono; Noriko Yanagitani; Fumiyoshi Ohyanagi; Makoto Nishio, ANTI-CANCER DRUGS, 28(5):565 - 567, Jun. 2017
  • Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer, Noboru Yamamoto; Yutaka Fujiwara; Kenji Tamura; Shunsuke Kondo; Satoru Iwasa; Yuko Tanabe; Atsushi Horiike; Noriko Yanagitani; Satoru Kitazono; Michiyasu Inatani; Jun Tanaka; Makoto Nishio, INVESTIGATIONAL NEW DRUGS, 35(1):37 - 46, Feb. 2017
  • Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer, Noboru Yamamoto; Yutaka Fujiwara; Kenji Tamura; Shunsuke Kondo; Satoru Iwasa; Yuko Tanabe; Atsushi Horiike; Noriko Yanagitani; Satoru Kitazono; Michiyasu Inatani; Jun Tanaka; Makoto Nishio, INVESTIGATIONAL NEW DRUGS, 35(1):37 - 46, Feb. 2017
  • 『煕朝詩薈』の収録詩 －近世漢詩総集『煕朝詩薈』についての基礎的研究（四）－, 高島 要; 奥村 栄; 坂尾 幸則; 文 敏景; 今清水 恒太; 矢部 三男; 中川 健; 宮内 栄作; 工藤 慶太; 堀池 篤; 大柳 文義; 西尾 誠人; 宝来 威; 元井 紀子; 二宮 浩範; 稲村 健太郎; 石川 雄一, 石川工業高等専門学校紀要, 49:60 - 46, 2017
  • 『煕朝詩薈』の収録詩 －近世漢詩総集『煕朝詩薈』についての基礎的研究（四）－, 高島 要; 奥村 栄; 坂尾 幸則; 文 敏景; 今清水 恒太; 矢部 三男; 中川 健; 宮内 栄作; 工藤 慶太; 堀池 篤; 大柳 文義; 西尾 誠人; 宝来 威; 元井 紀子; 二宮 浩範; 稲村 健太郎; 石川 雄一, 石川工業高等専門学校紀要, 49:60 - 46, 2017
  • Feasibility of EBUS-TBNA specimens for PD-L1 expression test in lung cancer., Yuichi Tambo; Rie Sakakibara; Noriko Motoi; Fumiyoshi Ohyanagi; Satoru Kitazono; Atsushi Horiike; Noriko Yanagitani; Tomoyo Oguri; Yosuke Kawashima; Natsuki Takano; Yuichi Ishikawa; Makoto Nishio, JOURNAL OF CLINICAL ONCOLOGY, 34(15), May 2016
  • Feasibility of EBUS-TBNA specimens for PD-L1 expression test in lung cancer., Yuichi Tambo; Rie Sakakibara; Noriko Motoi; Fumiyoshi Ohyanagi; Satoru Kitazono; Atsushi Horiike; Noriko Yanagitani; Tomoyo Oguri; Yosuke Kawashima; Natsuki Takano; Yuichi Ishikawa; Makoto Nishio, JOURNAL OF CLINICAL ONCOLOGY, 34(15), May 2016
  • Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer, Atsushi Horiike; Kengo Takeuchi; Takeshi Uenami; Yuko Kawano; Azusa Tanimoto; Kyohei Kaburaki; Yuichi Tambo; Keita Kudo; Noriko Yanagitani; Fumiyoshi Ohyanagi; Noriko Motoi; Yuichi Ishikawa; Takeshi Horai; Makoto Nishio, LUNG CANCER, 93:43 - 46, Mar. 2016
  • Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer, Atsushi Horiike; Kengo Takeuchi; Takeshi Uenami; Yuko Kawano; Azusa Tanimoto; Kyohei Kaburaki; Yuichi Tambo; Keita Kudo; Noriko Yanagitani; Fumiyoshi Ohyanagi; Noriko Motoi; Yuichi Ishikawa; Takeshi Horai; Makoto Nishio, LUNG CANCER, 93:43 - 46, Mar. 2016
  • P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer., Ryohei Katayama; Takuya Sakashita; Noriko Yanagitani; Hironori Ninomiya; Atsushi Horiike; Luc Friboulet; Justin F Gainor; Noriko Motoi; Akito Dobashi; Seiji Sakata; Yuichi Tambo; Satoru Kitazono; Shigeo Sato; Sumie Koike; A John Iafrate; Mari Mino-Kenudson; Yuichi Ishikawa; Alice T Shaw; Jeffrey A Engelman; Kengo Takeuchi; Makoto Nishio; Naoya Fujita, EBioMedicine, 3:54 - 66, Jan. 2016
  • P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer., Ryohei Katayama; Takuya Sakashita; Noriko Yanagitani; Hironori Ninomiya; Atsushi Horiike; Luc Friboulet; Justin F Gainor; Noriko Motoi; Akito Dobashi; Seiji Sakata; Yuichi Tambo; Satoru Kitazono; Shigeo Sato; Sumie Koike; A John Iafrate; Mari Mino-Kenudson; Yuichi Ishikawa; Alice T Shaw; Jeffrey A Engelman; Kengo Takeuchi; Makoto Nishio; Naoya Fujita, EBioMedicine, 3:54 - 66, Jan. 2016
  • A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer, S. Nishikawa; Y. Tambo; H. Ninomiya; T. Oguri; Y. Kawashima; N. Takano; S. Kitazono; F. Ohyanagi; A. Horiike; N. Yanagitani; Y. Ishikawa; M. Nishio, Annals of Oncology, 27(12):2300 - 2302, 2016
  • A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer, S. Nishikawa; Y. Tambo; H. Ninomiya; T. Oguri; Y. Kawashima; N. Takano; S. Kitazono; F. Ohyanagi; A. Horiike; N. Yanagitani; Y. Ishikawa; M. Nishio, Annals of Oncology, 27(12):2300 - 2302, 2016
  • A phase II study of carboplatin and pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer, Hironari Nishizawa; Atsushi Horiike; Ryota Saito; Fumiyoshi Ohyanagi; Keita Kudo; Noriko Yanagitani; Yuichi Tambo; Satoru Kitazono; Hiroshi Kobayashi; Makoto Nishio, Cancer Treatment and Research Communications, 9:100 - 105, 2016
  • A phase II study of carboplatin and pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer, Hironari Nishizawa; Atsushi Horiike; Ryota Saito; Fumiyoshi Ohyanagi; Keita Kudo; Noriko Yanagitani; Yuichi Tambo; Satoru Kitazono; Hiroshi Kobayashi; Makoto Nishio, Cancer Treatment and Research Communications, 9:100 - 105, 2016
  • Prognostic value of F-18-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer, Tsuneo Saga; Masayuki Inubushi; Mitsuru Koizumi; Kyosan Yoshikawa; Ming-Rong Zhang; Katsuyuki Tanimoto; Atsushi Horiike; Noriko Yanagitani; Fumiyoshi Ohyanagi; Makoto Nishio, CANCER SCIENCE, 106(11):1554 - 1560, Nov. 2015
  • Prognostic value of F-18-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer, Tsuneo Saga; Masayuki Inubushi; Mitsuru Koizumi; Kyosan Yoshikawa; Ming-Rong Zhang; Katsuyuki Tanimoto; Atsushi Horiike; Noriko Yanagitani; Fumiyoshi Ohyanagi; Makoto Nishio, CANCER SCIENCE, 106(11):1554 - 1560, Nov. 2015
  • Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors, Makoto Nishio; Haruyasu Murakami; Atsushi Horiike; Toshiaki Takahashi; Fumihiko Hirai; Naoko Suenaga; Takeshi Tajima; Kota Tokushige; Masami Ishii; Anthony Boral; Matthew Robson; Takashi Seto, JOURNAL OF THORACIC ONCOLOGY, 10(7):1058 - 1066, Jul. 2015
  • Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors, Makoto Nishio; Haruyasu Murakami; Atsushi Horiike; Toshiaki Takahashi; Fumihiko Hirai; Naoko Suenaga; Takeshi Tajima; Kota Tokushige; Masami Ishii; Anthony Boral; Matthew Robson; Takashi Seto, JOURNAL OF THORACIC ONCOLOGY, 10(7):1058 - 1066, Jul. 2015
  • Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer, Makoto Nishio; Atsushi Horiike; Haruyasu Murakami; Nobuyuki Yamamoto; Hiroyasu Kaneda; Kazuhiko Nakagawa; Hidehito Horinouchi; Masaki Nagashima; Masaru Sekiguchi; Tomohide Tamura, LUNG CANCER, 88(3):275 - 281, Jun. 2015
  • Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer, Makoto Nishio; Atsushi Horiike; Haruyasu Murakami; Nobuyuki Yamamoto; Hiroyasu Kaneda; Kazuhiko Nakagawa; Hidehito Horinouchi; Masaki Nagashima; Masaru Sekiguchi; Tomohide Tamura, LUNG CANCER, 88(3):275 - 281, Jun. 2015
  • Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer, Makoto Nishio; Atsushi Horiike; Hiroshi Nokihara; Hidehito Horinouchi; Shinji Nakamichi; Hiroshi Wakui; Fumiyoshi Ohyanagi; Keita Kudo; Noriko Yanagitani; Shunji Takahashi; Yasutoshi Kuboki; Noboru Yamamoto; Yasuhide Yamada; Masaichi Abe; Takashi Tahata; Tomohide Tamura, INVESTIGATIONAL NEW DRUGS, 33(3):632 - 640, Jun. 2015
  • Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer, Makoto Nishio; Atsushi Horiike; Hiroshi Nokihara; Hidehito Horinouchi; Shinji Nakamichi; Hiroshi Wakui; Fumiyoshi Ohyanagi; Keita Kudo; Noriko Yanagitani; Shunji Takahashi; Yasutoshi Kuboki; Noboru Yamamoto; Yasuhide Yamada; Masaichi Abe; Takashi Tahata; Tomohide Tamura, INVESTIGATIONAL NEW DRUGS, 33(3):632 - 640, Jun. 2015
  • Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation, Hisashi Tanaka; Atsushi Horiike; Toshio Sakatani; Ryota Saito; Noriko Yanagitani; Keita Kudo; Fumiyoshi Ohyanagi; Takeshi Horai; Makoto Nishio, ANTI-CANCER DRUGS, 26(5):573 - 578, Jun. 2015
  • Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation, Hisashi Tanaka; Atsushi Horiike; Toshio Sakatani; Ryota Saito; Noriko Yanagitani; Keita Kudo; Fumiyoshi Ohyanagi; Takeshi Horai; Makoto Nishio, ANTI-CANCER DRUGS, 26(5):573 - 578, Jun. 2015
  • Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer., Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T, Lung Cancer., S0169-5002(15):162, 2015
  • Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer., Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T, Lung Cancer., S0169-5002(15):162, 2015
  • Phase II Study of Docetaxel-plus-Bevacizumab Combination Therapy in Patients Previously Treated for Advanced Non-squamous Non-small Cell Lung Cancer, Fumiyoshi Ohyanagi; Noriko Yanagitani; Keita Kudo; Yuko Kawano; Toshio Sakatani; Azusa Tanimoto; Hironari Nishizawa; Atsushi Horiike; Sachiko Hagiwara; Takeshi Horai; Makoto Nishio, ANTICANCER RESEARCH, 34(9):5153 - 5158, Sep. 2014
  • Phase II Study of Docetaxel-plus-Bevacizumab Combination Therapy in Patients Previously Treated for Advanced Non-squamous Non-small Cell Lung Cancer, Fumiyoshi Ohyanagi; Noriko Yanagitani; Keita Kudo; Yuko Kawano; Toshio Sakatani; Azusa Tanimoto; Hironari Nishizawa; Atsushi Horiike; Sachiko Hagiwara; Takeshi Horai; Makoto Nishio, ANTICANCER RESEARCH, 34(9):5153 - 5158, Sep. 2014
  • A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC), Hidehito Horinouchi; Noboru Yamamoto; Hiroshi Nokihara; Takeshi Horai; Makoto Nishio; Fumiyoshi Ohyanagi; Atsushi Horiike; Kazuhiko Nakagawa; Masaaki Terashima; Takafumi Okabe; Hiroyasu Kaneda; Mark D. McKee; Dawn M. Carlson; Hao Xiong; Tomohide Tamura, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 74(1):37 - 43, Jul. 2014
  • A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC), Hidehito Horinouchi; Noboru Yamamoto; Hiroshi Nokihara; Takeshi Horai; Makoto Nishio; Fumiyoshi Ohyanagi; Atsushi Horiike; Kazuhiko Nakagawa; Masaaki Terashima; Takafumi Okabe; Hiroyasu Kaneda; Mark D. McKee; Dawn M. Carlson; Hao Xiong; Tomohide Tamura, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 74(1):37 - 43, Jul. 2014
  • Phase II Study of Erlotinib for Acquired Resistance to Gefitinib in Patients with Advanced Non-small Cell Lung Cancer, Atsushi Horiike; Nobuyuki Yamamoto; Hisashi Tanaka; Noriko Yanagitani; Keita Kudo; Fumiyoshi Ohyanagi; Akira Ono; Tateaki Naito; Haruyasu Murakami; Takeshi Horai; Makoto Nishio, ANTICANCER RESEARCH, 34(4):1975 - 1981, Apr. 2014
  • Phase II Study of Erlotinib for Acquired Resistance to Gefitinib in Patients with Advanced Non-small Cell Lung Cancer, Atsushi Horiike; Nobuyuki Yamamoto; Hisashi Tanaka; Noriko Yanagitani; Keita Kudo; Fumiyoshi Ohyanagi; Akira Ono; Tateaki Naito; Haruyasu Murakami; Takeshi Horai; Makoto Nishio, ANTICANCER RESEARCH, 34(4):1975 - 1981, Apr. 2014
  • A Feasibility Study of Carboplatin Plus Irinotecan Treatment for Elderly Patients with Extensive Disease Small-cell Lung Cancer, Yuki Misumi; Makoto Nishio; Toshiaki Takahashi; Fumiyoshi Ohyanagi; Atsushi Horiike; Haruyasu Murakami; Hirotsugu Kenmotsu; Nobuyuki Yamamoto; Mari Ishii; Tsuneo Shimokawa; Naoya Hida; Hiroaki Okamoto, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 44(2):116 - 121, Feb. 2014
  • A Feasibility Study of Carboplatin Plus Irinotecan Treatment for Elderly Patients with Extensive Disease Small-cell Lung Cancer, Yuki Misumi; Makoto Nishio; Toshiaki Takahashi; Fumiyoshi Ohyanagi; Atsushi Horiike; Haruyasu Murakami; Hirotsugu Kenmotsu; Nobuyuki Yamamoto; Mari Ishii; Tsuneo Shimokawa; Naoya Hida; Hiroaki Okamoto, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 44(2):116 - 121, Feb. 2014
  • PATTERNS OF RELAPSE AND PROGNOSIS AFTER CRIZOTINIB THERAPY FAILURE IN ALK plus NON-SMALL CELL LUNG CANCER, Noriko Yanagitani; Hironari Nishizawa; Ryohei Katayama; Hiroshi Kobayashi; Hiroshi Gyotoku; Takeshi Uenami; Yuichi Tambo; Keita Kudo; Fumiyoshi Ohyanagi; Atsushi Horiike; Hironori Ninomiya; Noriko Motoi; Kengo Takeuchi; Yuichi Ishikawa; Naoya Fujita; Takeshi Horai; Makoto Nishio, JOURNAL OF THORACIC ONCOLOGY, 8:S1188 - S1188, Nov. 2013
  • PATTERNS OF RELAPSE AND PROGNOSIS AFTER CRIZOTINIB THERAPY FAILURE IN ALK plus NON-SMALL CELL LUNG CANCER, Noriko Yanagitani; Hironari Nishizawa; Ryohei Katayama; Hiroshi Kobayashi; Hiroshi Gyotoku; Takeshi Uenami; Yuichi Tambo; Keita Kudo; Fumiyoshi Ohyanagi; Atsushi Horiike; Hironori Ninomiya; Noriko Motoi; Kengo Takeuchi; Yuichi Ishikawa; Naoya Fujita; Takeshi Horai; Makoto Nishio, JOURNAL OF THORACIC ONCOLOGY, 8:S1188 - S1188, Nov. 2013
  • SORAFENIB IN PATIENTS WITH RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER, Atsushi Horiike; Kengo Takeuchi; Takeshi Uenami; Yuko Kawano; Azusa Tanimoto; Kyohei Kaburaki; Hiroshi Kobayashi; Hiroshi Gyotoku; Hironari Nishizawa; Yuichi Tambo; Katsumi Nakatomi; Noriko Yanagitani; Fumiyoshi Ohyanagi; Sachiko Hagiwara; Noriko Motoi; Yuichi Ishikawa; Takeshi Horai; Makoto Nishio, JOURNAL OF THORACIC ONCOLOGY, 8:S898 - S898, Nov. 2013
  • SORAFENIB IN PATIENTS WITH RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER, Atsushi Horiike; Kengo Takeuchi; Takeshi Uenami; Yuko Kawano; Azusa Tanimoto; Kyohei Kaburaki; Hiroshi Kobayashi; Hiroshi Gyotoku; Hironari Nishizawa; Yuichi Tambo; Katsumi Nakatomi; Noriko Yanagitani; Fumiyoshi Ohyanagi; Sachiko Hagiwara; Noriko Motoi; Yuichi Ishikawa; Takeshi Horai; Makoto Nishio, JOURNAL OF THORACIC ONCOLOGY, 8:S898 - S898, Nov. 2013
  • Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor, Kazuko Sakai; Atsushi Horiike; Darryl L. Irwin; Keita Kudo; Yoshihiko Fujita; Azusa Tanimoto; Toshio Sakatani; Ryota Saito; Kyohei Kaburaki; Noriko Yanagitani; Fumiyoshi Ohyanagi; Makoto Nishio; Kazuto Nishio, CANCER SCIENCE, 104(9):1198 - 1204, Sep. 2013
  • Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor, Kazuko Sakai; Atsushi Horiike; Darryl L. Irwin; Keita Kudo; Yoshihiko Fujita; Azusa Tanimoto; Toshio Sakatani; Ryota Saito; Kyohei Kaburaki; Noriko Yanagitani; Fumiyoshi Ohyanagi; Makoto Nishio; Kazuto Nishio, CANCER SCIENCE, 104(9):1198 - 1204, Sep. 2013
  • Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer, M. Nishio; T. Horai; A. Horiike; H. Nokihara; N. Yamamoto; T. Takahashi; H. Murakami; N. Yamamoto; F. Koizumi; K. Nishio; W. Yusa; N. Koyama; T. Tamura, BRITISH JOURNAL OF CANCER, 109(3):538 - 544, Aug. 2013
  • Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer, M. Nishio; T. Horai; A. Horiike; H. Nokihara; N. Yamamoto; T. Takahashi; H. Murakami; N. Yamamoto; F. Koizumi; K. Nishio; W. Yusa; N. Koyama; T. Tamura, BRITISH JOURNAL OF CANCER, 109(3):538 - 544, Aug. 2013
  • Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: Phase ii study, Yuko Kawano; Fumiyoshi Ohyanagi; Noriko Yanagitani; Keita Kudo; Atsushi Horiike; Azusa Tanimoto; Hironari Nishizawa; Atsuo Ichikawa; Toshio Sakatani; Katsumi Nakatomi; Sachiko Hagiwara; Hironori Ninomiya; Noriko Motoi; Yuichi Ishikawa; Takeshi Horai; Makoto Nishio, Anticancer Research, 33(8):3327 - 3334, Aug. 2013
  • Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: Phase ii study, Yuko Kawano; Fumiyoshi Ohyanagi; Noriko Yanagitani; Keita Kudo; Atsushi Horiike; Azusa Tanimoto; Hironari Nishizawa; Atsuo Ichikawa; Toshio Sakatani; Katsumi Nakatomi; Sachiko Hagiwara; Hironori Ninomiya; Noriko Motoi; Yuichi Ishikawa; Takeshi Horai; Makoto Nishio, Anticancer Research, 33(8):3327 - 3334, Aug. 2013
  • Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer, Hideyuki Harada; Makoto Nishio; Haruyasu Murakami; Fumiyoshi Ohyanagi; Takuyo Kozuka; Satoshi Ishikura; Tateaki Naito; Kyoichi Kaira; Toshiaki Takahashi; Atsushi Horiike; Tetsuo Nishimura; Nobuyuki Yamamoto, Clinical Lung Cancer, 14(4):440 - 445, Jul. 2013
  • Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer, Hideyuki Harada; Makoto Nishio; Haruyasu Murakami; Fumiyoshi Ohyanagi; Takuyo Kozuka; Satoshi Ishikura; Tateaki Naito; Kyoichi Kaira; Toshiaki Takahashi; Atsushi Horiike; Tetsuo Nishimura; Nobuyuki Yamamoto, Clinical Lung Cancer, 14(4):440 - 445, Jul. 2013
  • A phase II study of S-1 in relapsed small cell lung cancer., Kudo K; Ohyanagi F; Horiike A; Miyauchi E; Tahanaka H; Yanagitani N; Saito R; Kaburaki K; Sakatani T; Horai T; Nishio M, Molecular and clinical oncology, 1(2):263 - 266, Mar. 2013
  • A phase II study of S-1 in relapsed small cell lung cancer., Kudo K; Ohyanagi F; Horiike A; Miyauchi E; Tahanaka H; Yanagitani N; Saito R; Kaburaki K; Sakatani T; Horai T; Nishio M, Molecular and clinical oncology, 1(2):263 - 266, Mar. 2013
  • ALK and EGFR mutation analysis in a phase II trial of cisplatin/pemetrexed in Japanese patients with advanced nonsquamous non-small cell lung cancer, Kyohei Kaburaki; Fumiyoshi Ohyanagi; Azusa Tanimoto; Toshio Sakatani; Yuko Kawano; Ryota Saito; Noriko Yanagitani; Keita Kudo; Atsushi Horiike; Sachiko Hagiwara; Noriko Motoi; Kengo Takeuchi; Yuichi Ishikawa; Takeshi Horai; Makoto Nishio, JOURNAL OF CLINICAL ONCOLOGY, 30(15), May 2012
  • ALK and EGFR mutation analysis in a phase II trial of cisplatin/pemetrexed in Japanese patients with advanced nonsquamous non-small cell lung cancer, Kyohei Kaburaki; Fumiyoshi Ohyanagi; Azusa Tanimoto; Toshio Sakatani; Yuko Kawano; Ryota Saito; Noriko Yanagitani; Keita Kudo; Atsushi Horiike; Sachiko Hagiwara; Noriko Motoi; Kengo Takeuchi; Yuichi Ishikawa; Takeshi Horai; Makoto Nishio, JOURNAL OF CLINICAL ONCOLOGY, 30(15), May 2012
  • Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations, Keita Kudo; Fumiyoshi Ohyanagi; Atushi Horiike; Eisaku Miyauchi; Noriko Yanagitani; Rira Hoshi; Yukitoshi Satoh; Noriko Motoi; Wakako Hamanaka; Yuichi Ishikawa; Mingyon Mun; Yukinori Sakao; Sakae Okumura; Ken Nakagawa; Takeshi Horai; Makoto Nishio, Lung Cancer, 74(3):401 - 404, Dec. 2011
  • Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations, Keita Kudo; Fumiyoshi Ohyanagi; Atushi Horiike; Eisaku Miyauchi; Noriko Yanagitani; Rira Hoshi; Yukitoshi Satoh; Noriko Motoi; Wakako Hamanaka; Yuichi Ishikawa; Mingyon Mun; Yukinori Sakao; Sakae Okumura; Ken Nakagawa; Takeshi Horai; Makoto Nishio, Lung Cancer, 74(3):401 - 404, Dec. 2011
  • Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma, Makoto Nishio; Takeharu Yamanaka; Kazuko Matsumoto; Hideharu Kimura; Kazuko Sakai; Asao Sakai; Takashi Sone; Atsushi Horiike; Fumiaki Koizumi; Kazuo Kasahara; Tatsuo Ohira; Norihiko Ikeda; Nagahiro Saijo; Tokuzo Arao; Kazuto Nishio, JOURNAL OF THORACIC ONCOLOGY, 6(11):1889 - 1894, Nov. 2011
  • Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma, Makoto Nishio; Takeharu Yamanaka; Kazuko Matsumoto; Hideharu Kimura; Kazuko Sakai; Asao Sakai; Takashi Sone; Atsushi Horiike; Fumiaki Koizumi; Kazuo Kasahara; Tatsuo Ohira; Norihiko Ikeda; Nagahiro Saijo; Tokuzo Arao; Kazuto Nishio, JOURNAL OF THORACIC ONCOLOGY, 6(11):1889 - 1894, Nov. 2011
  • Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer, A. Horiike; K. Kudo; E. Miyauchi; F. Ohyanagi; K. Kasahara; T. Horai; M. Nishio, BRITISH JOURNAL OF CANCER, 105(8):1131 - 1136, Oct. 2011
  • Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer, A. Horiike; K. Kudo; E. Miyauchi; F. Ohyanagi; K. Kasahara; T. Horai; M. Nishio, BRITISH JOURNAL OF CANCER, 105(8):1131 - 1136, Oct. 2011
  • A case of multiple cutaneous metastasis of lung cancer to the finger, Hisashi Tanaka; Keita Kudo; Noriko Yanagitani; Atsushi Horiike; Fumiyoshi Oyanagi; Makoto Nishio, Japanese Journal of Lung Cancer, 51(4):243 - 246, Aug. 2011
  • A case of multiple cutaneous metastasis of lung cancer to the finger, Hisashi Tanaka; Keita Kudo; Noriko Yanagitani; Atsushi Horiike; Fumiyoshi Oyanagi; Makoto Nishio, Japanese Journal of Lung Cancer, 51(4):243 - 246, Aug. 2011
  • [A case of adenocarcinoma of the lung with a pulmonary thromboembolism which improved with gefitinib]., Yanagitani N; Horiike A; Kudo K; Ohyanagi F; Nishio M; Horai T, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 49(4):282 - 286, Apr. 2011
  • [A case of adenocarcinoma of the lung with a pulmonary thromboembolism which improved with gefitinib]., Yanagitani N; Horiike A; Kudo K; Ohyanagi F; Nishio M; Horai T, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 49(4):282 - 286, Apr. 2011
  • Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Adenocarcinoma, Kazuo Kasahara; Tokuzo Arao; Kazuko Sakai; Kazuko Matsumoto; Asao Sakai; Hideharu Kimura; Takashi Sone; Atsushi Horiike; Makoto Nishio; Tatsuo Ohira; Norihiko Ikeda; Takeharu Yamanaka; Nagahiro Saijo; Kazuto Nishio, CLINICAL CANCER RESEARCH, 16(18):4616 - 4624, Sep. 2010
  • Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Adenocarcinoma, Kazuo Kasahara; Tokuzo Arao; Kazuko Sakai; Kazuko Matsumoto; Asao Sakai; Hideharu Kimura; Takashi Sone; Atsushi Horiike; Makoto Nishio; Tatsuo Ohira; Norihiko Ikeda; Takeharu Yamanaka; Nagahiro Saijo; Kazuto Nishio, CLINICAL CANCER RESEARCH, 16(18):4616 - 4624, Sep. 2010
  • A Phase 1 Clinical Study of Temsirolimus (CCI-779) in Japanese Patients with Advanced Solid Tumors, Yasuhito Fujisaka; Yasuhide Yamada; Noboru Yamamoto; Atsushi Horiike; Tomohide Tamura, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 40(8):732 - 738, Aug. 2010
  • A Phase 1 Clinical Study of Temsirolimus (CCI-779) in Japanese Patients with Advanced Solid Tumors, Yasuhito Fujisaka; Yasuhide Yamada; Noboru Yamamoto; Atsushi Horiike; Tomohide Tamura, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 40(8):732 - 738, Aug. 2010
  • Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer, F. Ohyanagi; N. Yamamoto; A. Horiike; H. Harada; T. Kozuka; H. Murakami; K. Gomi; T. Takahashi; M. Morota; T. Nishimura; M. Endo; Y. Nakamura; A. Tsuya; T. Horai; M. Nishio, BRITISH JOURNAL OF CANCER, 101(2):225 - 231, Jul. 2009
  • Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer, F. Ohyanagi; N. Yamamoto; A. Horiike; H. Harada; T. Kozuka; H. Murakami; K. Gomi; T. Takahashi; M. Morota; T. Nishimura; M. Endo; Y. Nakamura; A. Tsuya; T. Horai; M. Nishio, BRITISH JOURNAL OF CANCER, 101(2):225 - 231, Jul. 2009
  • A phase II study of S-1 for previously treated small cell lung cancer (SCLC), K. Kudo; F. Ohyanagi; A. Horiike; E. Miyauchi; I. Motokawa; T. Horai; M. Mun; Y. Sakao; S. Okumura; K. Nakagawa; M. Nishio, JOURNAL OF CLINICAL ONCOLOGY, 27(15), May 2009
  • A phase II study of S-1 for previously treated small cell lung cancer (SCLC), K. Kudo; F. Ohyanagi; A. Horiike; E. Miyauchi; I. Motokawa; T. Horai; M. Mun; Y. Sakao; S. Okumura; K. Nakagawa; M. Nishio, JOURNAL OF CLINICAL ONCOLOGY, 27(15), May 2009
  • Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors, Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Shimoyama; Yasuhide Yamada; Tomohide Tamura, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 61(3):489 - 496, Mar. 2008
  • Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors, Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Shimoyama; Yasuhide Yamada; Tomohide Tamura, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 61(3):489 - 496, Mar. 2008
  • Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer, Fumiyoshi Ohyanagi; Atsushi Horiike; Yoshio Okano; Yukitoshi Satoh; Sakae Okumura; Yuichi Ishikawa; Ken Nakagawa; Takeshi Horai; Makoto Nishio, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 61(3):503 - 508, Mar. 2008
  • Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer, Fumiyoshi Ohyanagi; Atsushi Horiike; Yoshio Okano; Yukitoshi Satoh; Sakae Okumura; Yuichi Ishikawa; Ken Nakagawa; Takeshi Horai; Makoto Nishio, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 61(3):503 - 508, Mar. 2008
  • Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer, Atsushi Horiike; Hideharu Kimura; Kazuto Nishio; Fumiyoshi Ohyanagi; Yukitoshi Satoh; Sakae Okumura; Yuichi Ishikawa; Ken Nakagawa; Takeshi Horai; Makoto Nishio, CHEST, 131(6):1628 - 1634, Jun. 2007
  • Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer, Atsushi Horiike; Hideharu Kimura; Kazuto Nishio; Fumiyoshi Ohyanagi; Yukitoshi Satoh; Sakae Okumura; Yuichi Ishikawa; Ken Nakagawa; Takeshi Horai; Makoto Nishio, CHEST, 131(6):1628 - 1634, Jun. 2007
  • Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors, Yasuhito Fujisaka; Atsushi Horiike; Toshio Shimizu; Noboru Yamamoto; Yasuhide Yamada; Tomohide Tamura, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 36(12):768 - 774, Dec. 2006
  • Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors, Yasuhito Fujisaka; Atsushi Horiike; Toshio Shimizu; Noboru Yamamoto; Yasuhide Yamada; Tomohide Tamura, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 36(12):768 - 774, Dec. 2006
  • A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors, Tomohide Tamura; Hironobu Minami; Yasuhide Yamada; Noboru Yamamoto; Tatsu Shimoyama; Haruyasu Murakami; Atsushi Horiike; Yasuhito Fujisaka; Tetsu Shinkai; Makoto Tahara; Kenji Kawada; Hiromichi Ebi; Yasutsuna Sasaki; Haiyi Jiang; Nagahiro Saijo, JOURNAL OF THORACIC ONCOLOGY, 1(9):1002 - 1009, Nov. 2006
  • A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors, Tomohide Tamura; Hironobu Minami; Yasuhide Yamada; Noboru Yamamoto; Tatsu Shimoyama; Haruyasu Murakami; Atsushi Horiike; Yasuhito Fujisaka; Tetsu Shinkai; Makoto Tahara; Kenji Kawada; Hiromichi Ebi; Yasutsuna Sasaki; Haiyi Jiang; Nagahiro Saijo, JOURNAL OF THORACIC ONCOLOGY, 1(9):1002 - 1009, Nov. 2006
  • Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients, Yasuhito Fujisaka; Tomohide Tamura; Yuichiro Ohe; Hideo Kunitoh; Ikuo Sekine; Noboru Yamamoto; Hiroshi Nokihara; Atsushi Horiike; Tetsuro Kodama; Nagahiro Saijo, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 36(8):477 - 482, Aug. 2006
  • Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients, Yasuhito Fujisaka; Tomohide Tamura; Yuichiro Ohe; Hideo Kunitoh; Ikuo Sekine; Noboru Yamamoto; Hiroshi Nokihara; Atsushi Horiike; Tetsuro Kodama; Nagahiro Saijo, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 36(8):477 - 482, Aug. 2006
  • Postoperative ischemic change in bronchial stumps after primary lung cancer resection, Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Atsushi Horiike; Fumiyoshi Ohyanagi; Makoto Nishio; Takeshi Horai; Yuichi Ishikawa, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 30(1):172 - 176, Jul. 2006
  • Postoperative ischemic change in bronchial stumps after primary lung cancer resection, Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Atsushi Horiike; Fumiyoshi Ohyanagi; Makoto Nishio; Takeshi Horai; Yuichi Ishikawa, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 30(1):172 - 176, Jul. 2006
  • Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days, Y Yamada; N Yamamoto; T Shimoyama; A Horiike; Y Fujisaka; K Takayama; T Sakamoto; Y Nishioka; S Yasuda; T Tamura, CANCER SCIENCE, 96(10):721 - 728, Oct. 2005
  • Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days, Y Yamada; N Yamamoto; T Shimoyama; A Horiike; Y Fujisaka; K Takayama; T Sakamoto; Y Nishioka; S Yasuda; T Tamura, CANCER SCIENCE, 96(10):721 - 728, Oct. 2005
  • Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients, M Nishio; F Ohyanagi; A Horiike; Y Ishikawa; Y Satoh; S Okumura; K Nakagawa; K Nishio; T Horai, BRITISH JOURNAL OF CANCER, 92(10):1877 - 1880, May 2005
  • Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients, M Nishio; F Ohyanagi; A Horiike; Y Ishikawa; Y Satoh; S Okumura; K Nakagawa; K Nishio; T Horai, BRITISH JOURNAL OF CANCER, 92(10):1877 - 1880, May 2005
  • Small-cell lung cancer: current therapy and novel agents., Horiike A; Saijo N, Oncology (Williston Park, N.Y.), 19(1):47 - 52; discussion 52, 54, Jan. 2005
  • Small-cell lung cancer: current therapy and novel agents., Horiike A; Saijo N, Oncology (Williston Park, N.Y.), 19(1):47 - 52; discussion 52, 54, Jan. 2005
  • Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience., Saijo N; Horiike A, Oncology (Williston Park, N.Y.), 18(7 Suppl 4):11 - 16, Jun. 2004
  • Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience., Saijo N; Horiike A, Oncology (Williston Park, N.Y.), 18(7 Suppl 4):11 - 16, Jun. 2004
  • Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma, Sekine, I; H Nokihara; A Horiike; N Yamamoto; H Kunitoh; Y Ohe; T Tamura; T Kodama; N Saijo, BRITISH JOURNAL OF CANCER, 90(6):1125 - 1128, Mar. 2004
  • Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma, Sekine, I; H Nokihara; A Horiike; N Yamamoto; H Kunitoh; Y Ohe; T Tamura; T Kodama; N Saijo, BRITISH JOURNAL OF CANCER, 90(6):1125 - 1128, Mar. 2004
  • Weekly administration of epoetin beta (EPOCH) for chemotherapy-induced anaemia in lung cancer patients: The results of a PK/PD study, Yasuhito Fujisaka; Tomohide Tamura; Yuichiro Ohe; Hideo Kunitoh; Ikuo Sekine; Noboru Yamamoto; Hiroshi Nokihara; Atsushi Horiike; Tetsuro Kodama; Nagahiro Saijo, ANNALS OF ONCOLOGY, 15:219 - 219, 2004
  • Weekly administration of epoetin beta (EPOCH) for chemotherapy-induced anaemia in lung cancer patients: The results of a PK/PD study, Yasuhito Fujisaka; Tomohide Tamura; Yuichiro Ohe; Hideo Kunitoh; Ikuo Sekine; Noboru Yamamoto; Hiroshi Nokihara; Atsushi Horiike; Tetsuro Kodama; Nagahiro Saijo, ANNALS OF ONCOLOGY, 15:219 - 219, 2004
  • [A case of the limited from of Wegener's granulomatosis without c-ANCA]., Ishii T; Bandoh S; Fujita J; Horiike A; Tojo Y; Kubo A; Yokomise H; Ishida T, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 41(11):834 - 839, Nov. 2003
  • [A case of the limited from of Wegener's granulomatosis without c-ANCA]., Ishii T; Bandoh S; Fujita J; Horiike A; Tojo Y; Kubo A; Yokomise H; Ishida T, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 41(11):834 - 839, Nov. 2003
  • Treatment of Small Cell Lung Cancer., Horiike A; Saijo N, Cancer research and treatment : official journal of Korean Cancer Association, 35(3):177 - 180, Jun. 2003
  • Treatment of Small Cell Lung Cancer., Horiike A; Saijo N, Cancer research and treatment : official journal of Korean Cancer Association, 35(3):177 - 180, Jun. 2003
  • Lung cancer with focal lymphocytic interstitial pneumonia, S Bandoh; J Fujita; R Haba; Y Tojo; A Horiike; T Okamoto; H Yokomise; K Satoh; S Kobayashi; T Ishida, INTERNAL MEDICINE, 41(11):997 - 1001, Nov. 2002
  • Lung cancer with focal lymphocytic interstitial pneumonia, S Bandoh; J Fujita; R Haba; Y Tojo; A Horiike; T Okamoto; H Yokomise; K Satoh; S Kobayashi; T Ishida, INTERNAL MEDICINE, 41(11):997 - 1001, Nov. 2002
  • Corticosteroid refractory radiation pneumonitis that remarkably responded to cyclosporin A, T Muraoka; S Bandoh; J Fujita; A Horiike; T Ishii; Y Tojo; A Kubo; T Ishida, INTERNAL MEDICINE, 41(9):730 - 733, Sep. 2002
  • Corticosteroid refractory radiation pneumonitis that remarkably responded to cyclosporin A, T Muraoka; S Bandoh; J Fujita; A Horiike; T Ishii; Y Tojo; A Kubo; T Ishida, INTERNAL MEDICINE, 41(9):730 - 733, Sep. 2002
  • [A case of pneumoconiosis in a dental technician]., Horiike A; Fujita J; Okitsu H; Bandoh S; Ishii T; Tojo Y; Okada H; Ishida T; Sato K; Yamadori I, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 40(7):579 - 582, Jul. 2002
  • [A case of pneumoconiosis in a dental technician]., Horiike A; Fujita J; Okitsu H; Bandoh S; Ishii T; Tojo Y; Okada H; Ishida T; Sato K; Yamadori I, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 40(7):579 - 582, Jul. 2002
  • Pulmonary lymphangiomyomatosis (LAM) developing chylothorax, Naofumi Morimoto; Shoji Hirasaki; Tadashi Kamei; Atsushi Horiike; Hirokazu Miyatake; Yuko Ogita; Hideharu Nakano, Internal Medicine, 39(9):738 - 741, 2000
  • Pulmonary lymphangiomyomatosis (LAM) developing chylothorax, Naofumi Morimoto; Shoji Hirasaki; Tadashi Kamei; Atsushi Horiike; Hirokazu Miyatake; Yuko Ogita; Hideharu Nakano, Internal Medicine, 39(9):738 - 741, 2000
  • Churg-Strauss syndrome with pleural involvement, Shoji Hirasaki; Tadashi Kamei; Yoko Iwasaki; Hirokazu Miyatake; Ikuko Hiratsuka; Atsushi Horiike; Yuko Ogita; Yoshiko Matsuhashi; Shuhei Yamamoto, Internal Medicine, 39(11):976 - 978, 2000
  • Churg-Strauss syndrome with pleural involvement, Shoji Hirasaki; Tadashi Kamei; Yoko Iwasaki; Hirokazu Miyatake; Ikuko Hiratsuka; Atsushi Horiike; Yuko Ogita; Yoshiko Matsuhashi; Shuhei Yamamoto, Internal Medicine, 39(11):976 - 978, 2000

Presentations

  • 医師主導治験におけるプロジェクトマネージャーと実施施設CRCとの情報共有の試み～今後の改善に向けて～, 竹ノ下祥子、深井しのぶ、山本明子、佐野良子、山口佳耶、西澤三保子、西岡信子、日比野文代、松下知司、堀池篤, 第23回CRCと臨床試験のあり方を考える会議in岡山, 16 Sep. 2023
  • Assessment and risk control sheet facilitates management in cancer drug therapy, 本間　織重;渡邊　知映;福地本　晴美;柏崎　純子;園生　容子;我妻　志保;細沼　雅弘;久保田　祐太郎;倉増　敦朗;堀池　篤;石田　博雄;嶋田　顕;角田　卓也;梅田　恵;吉村　清, 第59回日本癌治療学会学術集会, 23 Oct. 2021, 横浜・LIVE配信・オンデマンド配信
  • 抗PD-1抗体で発症せず、抗PD-L1抗体投与後に血球貪食症候群様の免疫関連有害事象を発症した肺癌症例, 有泉　裕嗣;吉村　清;堀池　篤;平澤　優弥;石黒　智之;大熊　遼太朗;久保田　祐太郎;濵田　和幸;和田　聡;鶴谷　純司;角田　卓也, 第25回日本がん免疫学会総会, 03 Jul. 2021, 和歌山
  • 体幹部定位放射線治療による肺合併症の実際, 楠本　壮二郎;岸野　康成;小林　玲;安藤　浩一;久保田　祐太郎;村上　幸三;堀池　篤;大森　亨;伊藤　芳紀;角田　卓也;相良　博典, 第61回日本肺癌学会学術集会, 14 Nov. 2020, 岡山およびライブ配信・オンデマンド配信
  • オンコマインDx Target Test マルチ CDx システム導入における Cancer Board での取り組み, 大熊　遼太朗;堀池　篤;楠本　壮二郎;三浦　咲子;井戸　愛;村上　幸三;遠藤　哲哉;矢持　淑子;扇谷　芳光;伊藤　芳紀;武井　秀史;相良　博典;角田　卓也, 第61回日本肺癌学会学術集会, 12 Nov. 2020, 岡山およびライブ配信・オンデマンド配信
  • PS良好PD-L1高発現NSCLCに対するPembrolizumab療法とプラチナ製剤併用＋Pembrolizumab療法の有効性の検討, 岸野　康成;楠本　壮二郎;堀池　篤;有泉　裕嗣;久保田　祐太郎;安藤　浩一;田中　明彦;大森　亨;角田　卓也;相良　博典, 第61回日本肺癌学会学術集会, 12 Nov. 2020, 岡山およびライブ配信・オンデマンド配信

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.